Lung volumes as possible factors explaining the heterogeneity in the response to elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease - Milan 2023

Cystic fibrosis in adults: a changing scene

Chair(s): Andrea Gramegna, Pilar Azevedo

Session type: Poster session

Lung volumes as possible factors explaining the heterogeneity in the response to elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease

Chiara Premuda

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Lung Clearance Index (LCI) and BMI are consistent with functional improvement in adult CF patients (pwCF) after elexacaftor/tezacaftor/ivacaftor (ETI) treatment

Francesca Lucca

Poster

Abstract

Clinical follow up after SARS-COV2 infection in Cystic Fibrosis patients

Ana Gomez Ortiz

Poster

Abstract

Clinical outcome of aminoglycoside therapy in Cystic Fibrosis patients, a single center experience.

Mona Allangawi

Poster

Abstract

Pulmonary function and quality of life in adults with cystic fibrosis: a cross-sectional analysis from the InSPIRE:CF trial

Natalia Smirnova

Poster

Abstract

Real-life experience using intravenous Fosfomycin in patients with Cystic Fibrosis and non-Cystic Fibrosis bronchiectasis

Luca Riberi

Poster

Abstract

Lung volumes as possible factors explaining the heterogeneity in the response to elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease

Chiara Premuda

Poster

Abstract

The impact of CFTR modulator therapy on body composition in patients with cystic fibrosis and advanced lung disease

Ivan Bambir

Poster

Abstract

Quality of life (QOL) of Tunisian patients with Cystic Fibrosis (CF)

Asma Knaz

Poster

Abstract

Nasal potential difference (NPD) and extended genetic analysis improve classification of CF and CFTR-related disorders: outcomes from a national difficult CF diagnosis (DCFD) service

Elif S. Agaoglu

Poster

Abstract

Real-Life Adverse Effects of the New Cystic Fibrosis Modulator Therapy

Amelia Simas Ribeiro

Poster

Abstract

Decreased mucolytic prescriptions in Phe508del homozygous Cystic Fibrosis Adults on Elexacaftor-tezacaftor-ivacaftor (Kaftrio/Trikafta)

Mohammed Azib Zahid

Poster

Abstract

Sweat Chloride Concentration as a Surrogate Marker of CFTR Modulator Therapy Response

Amelia Simas Ribeiro

Poster

Abstract

Effect of ETI on the degree of adherence to inhaled medication in adults with CF: a multi-center study in Greece.

Aikaterini Manika

Poster

Abstract

Evaluation of the therapeutic response to CFTR protein modulator treatments, in the management of patients with cystic fibrosis by lung ultrasound.

Sabrina Duval

Poster

Abstract

Long-term clinical outcomes of Elexacaftor/Tezacaftor/Ivacaftor therapy in adults with cystic fibrosis and severe lung disease

Daniela Savi

Poster

Abstract

Structural changes in lung morphology after modulating therapy with elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis

Valentina Fainardi

Poster

Abstract

Impact of CFTR modulators on lung transplant trends in people with cystic fibrosis in the US

Christian Merlo

Poster

Abstract

Cystic Fibrosis and Fit-to-Fly (CYFF Study)

Aina Akero

Poster

Abstract

Lower levels of bacterial aerobic respiration in sputum from people with cystic fibrosis with chronic lung infection

Mette Kolpen

Abstract

Forced oscillation technique for monitoring the respiratory status of adult cystic fibrosis patients

Anamarija Stajduhar

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}